“I’d like to congratulate the Arcinova team on building an exciting business, and I am thrilled to be joining forces.”
According to a press release, Quotient Sciences has acquired Arcinova early this month. The acquisition expands the former's service portfolio and will enable the integration of drug substance, drug product, and clinical testing capabilities. The press release appeared on Business Wire on 9th of this month.
Arcinova is a U.K.-based multiservice contract development, and manufacturing organization,
“I’d like to congratulate the Arcinova team on building an exciting business, and I am thrilled to be joining forces. Both businesses are similar in culture and aspire to help customers accelerate molecules from candidate selection through development and on to commercial launch,” said Mark Egerton, Ph.D., CEO of Quotient Sciences. “I’d also like to take this moment to thank our private equity partner, Permira, for supporting our ambitious growth plans.”
Quotient Sciences, again a U.K.-based company, is a drug development and manufacturing accelerator, providing integrated programs and tailored services across the entire development pathway.
“Since inception, we set out to build a unique organization that accelerates the development of new medicines for patients in need. We are delighted to move on to the next stage with Quotient as the perfect partner for Arcinova. Deep science, agility, flexibility, and the drive for customer service excellence are the cornerstones of both businesses. I look forward to working with the Quotient team and Permira to deliver even greater value for our customers,” said Professor Ian Shott, CBE, co-founder, and Executive Chairman of Arcinova.
All the quotes used in this piece belong to the press release. There was no direct communication between these companies and The Silicon Review.